


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims

1. (original) A compound of formula (I):



(I)

wherein:

R¹ is one or more substituents independently selected from hydrogen, hydroxy, CN, N(R^aR^b), C₁₋₈alkyl, C₃₋₇ cycloalkyl, halogen and C₁₋₈ alkoxy;

R² is selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, C₆₋₁₄ aryl, heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, halogen, CN, NO₂, OR^a, N(R^aR^b), S(O)_mR^a, SR^a, OS(O)_mR^a, S(O)_mOR^a, OS(O)_mOR^a, N(R^a)S(O)_mR^b, S(O)_mN(R^aR^b), N(R^a)S(O)_mN(R^aR^b), OS(O)_mN(R^aR^b), N(R^a)S(O)_mOR^b, C(O)R^a, OC(O)R^a, C(O)OR^a, OC(O)OR^a, N(R^a)C(O)R^b, C(O)N(R^aR^b), N(R^a)C(O)N(R^aR^b), OC(O)N(R^aR^b), N(R^a)C(O)OR^b, C(NR^aR^b)=N(R^a), N(R^a)C(NR^aR^b)=N(R^a), C(SR^a)=N(R^b), C(OR^a)=N(R^b), N(R^a)C(SR^a)=N(R^b) and heterocycle optionally substituted with oxo or R^a;

or optionally when R² is C₅₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₅₋₇ cycloalkenyl, C₆₋₁₄ aryl or heterocycle R² may be fused to 5-7 membered carbocyclic or heterocyclic rings;

R^a and R^b are independently hydrogen, NO₂, OR^c, CN, N(R^cR^d), C(O)R^c, C(O)C(O)R^c, C(O)N(R^cR^d), C(O)C(O)N(R^cR^d), S(O)_mR^c, SR^c, S(O)_mN(R^cR^d), C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, C₆₋₁₄ aryl or heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, C₆₋₁₄ aryl, CN, NO₂, OR^c, N(R^cR^d), S(O)_mR^c, SR^c, OS(O)_mR^c, S(O)_mOR^c, OS(O)_mOR^c, N(R^c)S(O)_mR^d, S(O)_mN(R^cR^d), N(R^c)S(O)_mN(R^cR^d), OS(O)_mN(R^cR^d), N(R^c)S(O)_mOR^d, C(O)R^c, OC(O)R^c, C(O)OR^c, OC(O)OR^c, N(R^c)C(O)R^d, C(O)N(R^cR^d), N(R^c)C(O)N(R^cR^d), OC(O)N(R^cR^d), N(R^c)C(O)OR^d, C(NR^cR^d)=N(R^c), C(SR^c)=N(R^d), C(OR^c)=N(R^d) and heterocycle;

Optionally, R^a and R^b may be linked together through one or more ring carbon atoms and/or ring heteroatoms including N, O, C(R^cR^d), C(O), S(O)_m, or S to form a saturated or unsaturated 3 to 8 membered carbocyclic or heterocyclic ring;

R^c and R^d are independently hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, C₆₋₁₄ aryl or heterocycle;

Optionally, R^c and R^d may be linked together through one or more ring carbon atoms and/or ring heteroatoms including N, O, C(O) and S(O)_m, or S to form a saturated or unsaturated 3 to 8 membered carbocyclic or heterocyclic ring;

R³ is hydrogen, hydroxy, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, N(R^aR^b), or heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, halogen, oxo, CN, NO₂, OR^a, N(R^aR^b), S(O)_mR^a, SR^a, OS(O)_mR^a, S(O)_mOR^a, OS(O)_mOR^a,

Preliminary Amendment

$N(R^a)S(O)_mR^b$, $S(O)_mN(R^aR^b)$, $N(R^a)S(O)_mN(R^aR^b)$, $OS(O)_mN(R^aR^b)$, $N(R^a)S(O)_mOR^b$, $C(O)R^a$, $OC(O)R^a$, $C(O)OR^a$, $OC(O)OR^a$, $N(R^a)C(O)R^b$, $C(O)N(R^aR^b)$, $N(R^a)C(O)N(R^aR^b)$, $OC(O)N(R^aR^b)$, $N(R^a)C(O)OR^b$, $C(NR^a)=N(R^b)$, $C(SR^a)=N(R^b)$, $C(OR^a)=N(R^b)$, $N(R^a)C(NR^aR^b)=N(R^a)$, $N(R^a)C(SR^a)=N(R^b)$, $N(R^a)C(OR^b)=N(R^b)$, and heterocycle optionally substituted by oxo or R^a ;


m is 1 or 2;

or a pharmaceutically acceptable salt thereof, provided that:

(a) when R^1 and R^2 are both hydrogen, then R^3 cannot be C_{1-8} alkyl substituted with $N(R^aR^b)$ where R^a and R^b are both C_{1-8} alkyl;

(b) when R^1 is halogen and R^2 is C_{1-8} alkyl, C_{1-8} alkyl substituted with $C(O)R^a$ where R^a is C_{1-8} alkyl, or R^2 is C_{1-8} alkyl substituted with $S(O)_mR^a$ where R^a is C_{1-8} alkyl and m is 2, then R^3 cannot be C_{1-8} alkyl or C_{1-8} alkyl substituted with OR^a where R^a is C_{1-8} alkyl.

2. (original) A compound of formula (I)



wherein:

R¹ is hydrogen or halogen;

R^2 is

- (a) hydrogen;
- (b) C₁₋₈alkyl optionally substituted with C₃₋₇cycloalkyl, OR^a, N(R^aR^b), C(O)R^a, C(O)N(R^aR^b), or heterocycle optionally substituted with oxo or R^a; or
- (c) C₆₋₁₄aralkyl optionally substituted with S(O)_mR^a or R^a; wherein m is 2;

\mathbb{R}^3 is

- (a) C_{1-8} alkyl optionally substituted with C_{1-8} alkyl, C_{3-7} cycloalkyl, OR^a , SR^a , $C(O)N(R^aR^b)$, $NR^aC(O)R^b$, or heterocycle optionally substituted with oxo or R^a ;
- (b) C_{3-7} cycloalkyl;
- (c) C_{1-8} haloalkyl;
- (d) heterocycle optionally substituted with oxo; or
- (e) $N(R^aR^b)$;


wherein: R^a and R^b are independently hydrogen, OR^c , SR^c , C_{1-8} alkyl, C_{6-14} aryl or heterocycle, each of which each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl, CN , NO_2 , OR^c , $N(R^cR^d)$, $S(O)_mR^c$, SR^c , $OS(O)_mR^c$, $S(O)_mOR^c$, $OS(O)_mOR^c$, $N(R^c)S(O)_mR^d$, $S(O)_mN(R^cR^d)$, $N(R^c)S(O)_mN(R^cR^d)$, $OS(O)_mN(R^cR^d)$, $N(R^c)S(O)_mOR^d$, $C(O)R^k$, $OC(O)R^c$, $C(O)OR^c$, $OC(O)OR^c$, $N(R^c)C(O)R^d$, $C(O)N(R^cR^d)$, $N(R^c)C(O)N(R^cR^d)$, $OC(O)N(R^cR^d)$, $N(R^c)C(O)OR^d$, $C(NR^cR^d)=N(R^c)$, $C(SR^c)=N(R^d)$, $C(OR^c)=N(R^d)$ and heterocycle; wherein R^c is hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl or heterocycle;

R^c and R^d are independently hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl or heterocycle;

or a pharmaceutically acceptable salt thereof provided that

- (a) when R^1 and R^2 are both hydrogen, then R^3 cannot be C_{1-8} alkyl substituted with $N(R^aR^b)$ where R^a and R^b are both C_{1-8} alkyl;
- (b) when R^1 is halogen and R^2 is C_{1-8} alkyl, C_{1-8} alkyl substituted with $C(O)R^a$ where R^a is C_{1-8} alkyl, then R^3 cannot be C_{1-8} alkyl or C_{1-8} alkyl substituted with OR^a where R^a is C_{1-8} alkyl.

3. (original) A compound of formula (I)



wherein:

R¹ is hydrogen or halogen;

R² is

(a) hydrogen;

(b) C₁₋₈alkyl optionally substituted with C₃₋₇cycloalkyl, OR^a, N(R^aR^b), C(O)R^a, C(O)N(R^aR^b), or heterocycle optionally substituted with oxo or R^a; or
(c) C₆₋₁₄aralkyl optionally substituted with S(O)_mR^a or R^a; wherein m is 2;

R³ is

(a) C₁₋₈alkyl optionally substituted with C₁₋₈alkyl, C₃₋₇cycloalkyl, OR^a, SR^a, C(O)N(R^aR^b), NR^aC(O)R^b, or heterocycle optionally substituted with oxo or R^a;
(b) C₃₋₇cycloalkyl;
(c) C₁₋₈haloalkyl;
(d) heterocycle optionally substituted with oxo; or
(e) N(R^aR^b);


wherein R^a and R^b are independently hydrogen, NO₂, OR^c, C(O)R^c, C₁₋₈alkyl optionally substituted with OR^c, C₆₋₁₄aryl or heterocycle;

wherein R^c is hydrogen, C₁₋₈alkyl or C₆₋₁₄aryl;

or a pharmaceutically acceptable salt thereof provided that

- (a) when R¹ and R² are both hydrogen, then R³ cannot be C₁₋₈alkyl substituted with N(R^aR^b) where R^a and R^b are both C₁₋₈alkyl;
- (b) when R¹ is halogen and R² is C₁₋₈alkyl, C₁₋₈alkyl substituted with C(O)R^a where R^a is C₁₋₈alkyl, then R³ cannot be C₁₋₈alkyl or C₁₋₈alkyl substituted with OR^a where R^a is C₁₋₈alkyl;

4. (original) A compound of formula (I)



wherein:

R¹ is hydrogen or halogen;

R² is

(a) hydrogen;

(b) C₁₋₈alkyl substituted with C₃₋₇cycloalkyl, C(O)R^a wherein R^a is heterocycle, or heterocycle optionally substituted with oxo; or

(c) C₆₋₁₄aralkyl optionally substituted with S(O)_mR^a wherein R^a is C₁₋₈alkyl and m is 2;

R³ is

(a) C₁₋₈alkyl optionally substituted with C₁₋₈alkyl, C₃₋₇cycloalkyl, OR^a, SR^a, C(O)N(R^aR^b), NR^aC(O)R^b, or heterocycle optionally substituted with oxo or R^a, wherein R^a and R^b are independently hydrogen, NO₂, OR^c, C(O)R^c, C₁₋₈alkyl optionally substituted with OR^c, C₆₋₁₄aryl or heterocycle;

(b) C₃₋₇cycloalkyl;

(c) C₁₋₈haloalkyl;


(d) heterocycle optionally substituted with oxo; or

(e) N(R^aR^b) wherein R^a and R^b are independently hydrogen, NO₂, OR^c, C(O)R^c, C₁₋₈alkyl optionally substituted with OR^c, C₆₋₁₄aryl or heterocycle;

wherein R^c is hydrogen, C₁₋₈alkyl or C₆₋₁₄aryl;

or a pharmaceutically acceptable salt thereof.

5. (original) A compound of formula (Ia)



wherein:

R^2 is selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl, heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, halogen, CN, NO_2 , OR^a , $N(R^aR^b)$, $S(O)_mR^a$, SR^a , $OS(O)_mR^a$, $S(O)_mOR^a$, $OS(O)_mOR^a$, $N(R^a)S(O)_mR^b$, $S(O)_mN(R^aR^b)$, $N(R^a)S(O)_mN(R^aR^b)$, $OS(O)_mN(R^aR^b)$, $N(R^a)S(O)_mOR^b$, $C(O)R^a$, $OC(O)R^a$, $C(O)OR^a$, $OC(O)OR^a$, $N(R^a)C(O)R^b$, $C(O)N(R^aR^b)$, $N(R^a)C(O)N(R^aR^b)$, $OC(O)N(R^aR^b)$, $N(R^a)C(O)OR^b$, $C(NR^aR^b)=N(R^a)$, $N(R^a)C(NR^aR^b)=N(R^a)$, $C(SR^a)=N(R^b)$, $C(OR^a)=N(R^b)$, $N(R^a)C(SR^a)=N(R^b)$ and heterocycle optionally substituted with oxo or R^a ;
or optionally when R^2 is C_{5-7} cycloalkyl, C_{6-14} aralkyl, C_{5-7} cycloalkenyl, C_{6-14} aryl or heterocycle R^2 may be fused to 5-7 membered carbocyclic or heterocyclic rings;

R^a and R^b are independently hydrogen, NO_2 , OR^c , CN, $N(R^cR^d)$, $C(O)R^c$, $C(O)C(O)R^c$, $C(O)N(R^cR^d)$, $C(O)C(O)N(R^cR^d)$, $S(O)_mR^c$, SR^c , $S(O)_mN(R^cR^d)$, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl or heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl, CN, NO_2 , OR^c , $N(R^cR^d)$, $S(O)_mR^c$, SR^c , $OS(O)_mR^c$, $S(O)_mOR^c$, $OS(O)_mOR^c$, $N(R^c)S(O)_mR^d$, $S(O)_mN(R^cR^d)$, $N(R^c)S(O)_mN(R^cR^d)$, $OS(O)_mN(R^cR^d)$, $N(R^c)S(O)_mOR^d$, $C(O)R^c$, $OC(O)R^c$, $C(O)OR^c$,

OC(O)OR^c, N(R^c)C(O)R^d, C(O)N(R^cR^d), N(R^c)C(O)N(R^cR^d), OC(O)N(R^cR^d), N(R^c)C(O)OR^d, C(NR^cR^d)=N(R^c), C(SR^c)=N(R^d), C(OR^c)=N(R^d) and heterocycle;

Optionally, R^a and R^b may be linked together through one or more ring carbon atoms and/or ring heteroatoms including N, O, C(R^cR^d), C(O), S(O)_m or S to form a saturated or unsaturated 3 to 8 membered carbocyclic or heterocyclic ring;

R^c and R^d are independently hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₆₋₁₄ aralkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, C₆₋₁₄ aryl or heterocycle;

Optionally, R^c and R^d may be linked together through one or more ring carbon atoms and/or ring heteroatoms including N, O, C(O) and S(O)_m, or S to form a saturated or unsaturated 3 to 8 membered carbocyclic or heterocyclic ring;

R³ is hydrogen, hydroxy, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, N(R^aR^b), or heterocycle, each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkenyl, C₃₋₆ alkynyl, halogen, oxo, CN, NO₂, OR^a, N(R^aR^b), S(O)_mR^a, SR^a, OS(O)_mR^a, S(O)_mOR^a, OS(O)_mOR^a, N(R^a)S(O)_mR^b, S(O)_mN(R^aR^b), N(R^a)S(O)_mN(R^aR^b), OS(O)_mN(R^aR^b), N(R^a)S(O)_mOR^b, C(O)R^a, OC(O)R^a, C(O)OR^a, OC(O)OR^a, N(R^a)C(O)R^b, C(O)N(R^aR^b), N(R^a)C(O)N(R^aR^b), OC(O)N(R^aR^b), N(R^a)C(O)OR^b, C(NR^a)=N(R^b), C(SR^a)=N(R^b), C(OR^a)=N(R^b), N(R^a)C(NR^aR^b)=N(R^a), N(R^a)C(SR^a)=N(R^b), N(R^a)C(OR^a)=N(R^b), and heterocycle optionally substituted by oxo or R^a;

m is 1 or 2;

or a pharmaceutically acceptable salt thereof, provided that:

when R² is C₁₋₈ alkyl, C₁₋₈ alkyl substituted with C(O)R^a where R^a is C₁₋₈ alkyl, or R² is C₁₋₈ alkyl substituted with S(O)_mR^a where R^a is C₁₋₈ alkyl and m is 2, then R³ cannot be C₁₋₈ alkyl or C₁₋₈ alkyl substituted with OR^a where R^a is C₁₋₈ alkyl.

6. (original) A compound of formula (Ia) according to claim 5 wherein:

R^2 is

- (a) hydrogen;
- (b) C_{1-8} alkyl optionally substituted with C_{3-7} cycloalkyl, OR^a , $N(R^aR^b)$, $C(O)R^a$, $C(O)N(R^aR^b)$, or heterocycle optionally substituted with oxo or R^a ; or
- (c) C_{6-14} aralkyl optionally substituted with $S(O)_mR^a$ or R^a ; wherein m is 2;

R^3 is

- (a) C_{1-8} alkyl optionally substituted with C_{1-8} alkyl, C_{3-7} cycloalkyl, OR^a , SR^a , $C(O)N(R^aR^b)$, $NR^aC(O)R^b$, or heterocycle optionally substituted with oxo or R^a ;
- (b) C_{3-7} cycloalkyl;
- (c) C_{1-8} haloalkyl;
- (d) heterocycle optionally substituted with oxo; or
- (e) $N(R^aR^b)$;

wherein R^a and R^b are independently hydrogen, OR^c , SR^c , C_{1-8} alkyl, C_{6-14} aryl or heterocycle, each of which each of which may be optionally substituted with one or more substituents independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl, CN , NO_2 , OR^c , $N(R^cR^d)$, $S(O)_mR^c$, SR^c , $OS(O)_mR^c$, $S(O)_mOR^c$, $OS(O)_mOR^c$, $N(R^c)S(O)_mR^d$, $S(O)_mN(R^cR^d)$, $N(R^c)S(O)_mN(R^cR^d)$, $OS(O)_mN(R^cR^d)$, $N(R^c)S(O)_mOR^d$, $C(O)R^c$, $OC(O)R^c$, $C(O)OR^c$, $OC(O)OR^c$, $N(R^c)C(O)R^d$, $C(O)N(R^cR^d)$, $N(R^c)C(O)N(R^cR^d)$, $OC(O)N(R^cR^d)$, $N(R^c)C(O)OR^d$, $C(NR^cR^d)=N(R^c)$, $C(SR^c)=N(R^d)$, $C(OR^c)=N(R^d)$ and heterocycle; wherein R^c is hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl or heterocycle;

R^c and R^d are independently hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-7} cycloalkyl, C_{6-14} aralkyl, C_{2-6} alkenyl, C_{3-7} cycloalkenyl, C_{3-6} alkynyl, C_{6-14} aryl or heterocycle;

or a pharmaceutically acceptable salt thereof provided that

when R^2 is C_{1-8} alkyl, C_{1-8} alkyl substituted with $C(O)R^a$ where R^a is C_{1-8} alkyl, then R^3 cannot be C_{1-8} alkyl or C_{1-8} alkyl substituted with OR^a where R^a is C_{1-8} alkyl.

7. (original) A compound of formula (Ia) according to claim 5 wherein:

R^2 is

- (a) hydrogen;
- (b) C_{1-8} alkyl optionally substituted with C_{3-7} cycloalkyl, OR^a , $N(R^aR^b)$, $C(O)R^a$, $C(O)N(R^aR^b)$, or heterocycle optionally substituted with oxo or R^a ; or
- (c) C_{6-14} aralkyl optionally substituted with $S(O)_mR^a$ or R^a ; wherein m is 2;

R^3 is

- (a) C_{1-8} alkyl optionally substituted with C_{1-8} alkyl, C_{3-7} cycloalkyl, OR^a , SR^a , $C(O)N(R^aR^b)$, $NR^aC(O)R^b$, or heterocycle optionally substituted with oxo or R^a ;
- (b) C_{3-7} cycloalkyl;
- (c) C_{1-8} haloalkyl;
- (d) heterocycle optionally substituted with oxo; or
- (e) $N(R^aR^b)$;

wherein R^a and R^b are independently hydrogen, NO_2 , OR^c , $C(O)R^c$, C_{1-8} alkyl optionally substituted with OR^c , C_{6-14} aryl or heterocycle;

wherein R^c is hydrogen, C_{1-8} alkyl or C_{6-14} aryl;

or a pharmaceutically acceptable salt thereof provided that

when R^2 is C_{1-8} alkyl, C_{1-8} alkyl substituted with $C(O)R^a$ where R^a is C_{1-8} alkyl, then R^3 cannot be C_{1-8} alkyl or C_{1-8} alkyl substituted with OR^a where R^a is C_{1-8} alkyl.

8. (original) A compound of formula (Ia) according to claim 5 wherein:

R^2 is

- (a) hydrogen;

- (b) C_{1-8} alkyl substituted with C_{3-7} cycloalkyl, $C(O)R^a$ wherein R^a is heterocycle, or heterocycle optionally substituted with oxo; or
- (c) C_{6-14} aralkyl optionally substituted with $S(O)_mR^a$ wherein R^a is C_{1-8} alkyl and m is 2;

R^3 is

- (a) C_{1-8} alkyl optionally substituted with C_{1-8} alkyl, C_{3-7} cycloalkyl, OR^a , SR^a , $C(O)N(R^aR^b)$, $NR^aC(O)R^b$, or heterocycle optionally substituted with oxo or R^a ; wherein R^a and R^b are independently hydrogen, NO_2 , OR^c , $C(O)R^c$, C_{1-8} alkyl optionally substituted with OR^c , C_{6-14} aryl or heterocycle;
- (b) C_{3-7} cycloalkyl;
- (c) C_{1-8} haloalkyl;
- (d) heterocycle optionally substituted with oxo; or
- (e) $N(R^aR^b)$ wherein R^a and R^b are independently hydrogen, NO_2 , OR^c , $C(O)R^c$, C_{1-8} alkyl optionally substituted with OR^c , C_{6-14} aryl or heterocycle;

wherein R^c is hydrogen, C_{1-8} alkyl or C_{6-14} aryl;

or a pharmaceutically acceptable salt thereof.

9. (original) A compound of formula (I) according to claim 1 wherein R^1 is one or more substituents independently selected from hydroxy, CN, $N(R^aR^b)$, C_{1-8} alkyl, C_{3-7} cycloalkyl, halogen and C_{1-8} alkoxy; or a pharmaceutically acceptable salt thereof.

10. (currently amended) A compound of formula (Ia) according to any of claims 5-7 claim 5 wherein R^2 is C_{1-8} alkyl optionally substituted with $C(O)N(R^aR^b)$, wherein R^a and R^b are independently hydrogen or C_{1-8} alkyl and R^3 is C_{1-8} alkyl optionally substituted with OR^a , wherein OR^a is hydrogen or C_{1-8} alkyl, or a pharmaceutically acceptable salt thereof.

11. (original) A compound selected from the group consisting of:
7-(4-fluorobenzyl)-4-hydroxy- N -(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-benzyl-*N*-(cyclopropylmethyl)-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-*N*-(pyridin-4-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-*N*,4-dihydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopropyl-7-(4-fluorobenzyl)-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-morpholin-4-ylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-*N*-(2-methylpropyl)-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cycloheptyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopentyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclobutyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-2-oxo-*N*-(2-phenylethyl)-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-2-oxo-*N*-(1-phenylethyl)-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-(Cyclohexylmethyl)-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-(2-Furanylmethyl)-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclohexyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-2-oxo-7-(phenylmethyl)-N-(2-thienylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopropyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclobutyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopropyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-*N*-(2-furanylmethyl)-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-[2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

(\pm)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-(tetrahydro-2-furanylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-(2-(1-piperidinyl)ethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-(4-pyridinylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-(2-pyridinylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-(3-pyridinylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-*N*-(hexahydro-1*H*-azepin-1-yl)-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(5-Fluoro-2-pyridinyl)methyl]-4-hydroxy-*N*-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-N-[2-(2-pyridinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(1*H*-imidazol-4-yl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
Benzyl-*N*-cyclobutyl-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-*N*-cyclopropyl-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-*N*-cyclobutyl-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-*N*-(2-furylmethyl)-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-*N*-cyclopropyl-4-hydroxy-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-*N*-(pyridin-4-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-*N*-(pyridin-4-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-1-(cyclopropylmethyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-*N*-cyclobutyl-1-(cyclopropylmethyl)-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide ;
7-Benzyl-*N*-cyclobutyl-4-hydroxy-1-(2-morpholin-4-ylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-*N*-(3-morpholin-4-ylpropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-*N*-(2-pyrrolidin-1-ylethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-*N*-cyclobutyl-4-hydroxy-2-oxo-1-(1,3-thiazol-2-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1-(1,3-thiazol-2-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-*N*-(pyridin-4-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-2-oxo-*N*-(pyridin-3-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-1-[4-(methylsulfonyl)benzyl]-*N*-(2-morpholin-4-ylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-(2-Furanylmethyl)-4-hydroxy-1-[(4-nitrophenyl)methyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-*N*-[2-(methyloxy)ethyl]-1-[(4-nitrophenyl)methyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclobutyl-4-hydroxy-1-[(4-nitrophenyl)methyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[(4-Aminophenyl)methyl]-*N*-cyclobutyl-4-hydroxy-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

and pharmaceutically acceptable salts thereof.

12. (original) A compound selected from the group consisting of:

7-(4-fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopropyl-7-(4-fluorobenzyl)-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-morpholin-4-ylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
4-Hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(5-Fluoro-2-pyridinyl)methyl]-4-hydroxy-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-1-(cyclopropylmethyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-(1,3-thiazol-2-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
and pharmaceutically acceptable salts thereof.

13. (original) A compound selected from the group consisting of:

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide sodium salt;

1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

Sodium 1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-3-[(methylamino)carbonyl]-2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(methylamino)-2-oxoethyl]-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

Sodium 1-[2-(dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-3-({[2-(methyloxy)ethyl]amino}carbonyl)-2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate;

7-(4-Fluorobenzyl)-4-hydroxy-N-[(2*R*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

Sodium 7-[(4-fluorophenyl)methyl]-3-({[(2*R*)-2-hydroxypropyl]amino}carbonyl)-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridin-4-olate;

7-(4-Fluorobenzyl)-4-hydroxy-N-[(2*S*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-(2-Amino-2-oxoethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-(4-Fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

Sodium 1-(4-fluorophenyl)-7-[(4-fluorophenyl)methyl]-3-{{[(2-hydroxyethyl)amino]carbonyl}-2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate;

N-[(2*R*)-2,3-Dihydroxypropyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

Sodium 7-[(4-fluorophenyl)methyl]-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-3-({[2-(methyloxy)ethyl]amino}carbonyl)-2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate; 1-Ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1*S*)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide; Sodium 1-ethyl-7-[(4-fluorophenyl)methyl]-3-({[(1*S*)-2-hydroxy-1-methylethyl]amino}carbonyl)-2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate; and pharmaceutically acceptable salts thereof.

14. (original) A compound selected from the group consisting of:
7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-hydroxypropyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(Ethyoxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-[methyl(methylsulfonyl)amino]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(\pm)-1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-N-[2-[methyl(methylsulfonyl)amino]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-N-{2-[(1-methylethyl)sulfonyl]ethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Cyclopropylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[(Dimethylamino)carbonyl](methyl)amino]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxypropyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[*(2S*)-2-hydroxypropyl]-1-[3-(methyloxy)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxybutyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-1-{2-[(2-methoxyethyl)amino]-2-oxoethyl}-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(2-oxo-1-piperidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxypropyl)-2-oxo-1-[3-(2-oxohexahydro-1*H*-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[*(1S*)-2-hydroxy-1-methylethyl]-2-oxo-1-[3-(2-oxohexahydro-1*H*-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(2-oxohexahydro-1*H*-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
and pharmaceutically acceptable salts thereof.

15. (currently amended) A compound selected from the group consisting of examples numbers 2, 9, 10, 12, 17, 28, 36, 37, 45, 49, 50, 54, 62, 64, 83, 84, 85, 86, 89, 91, 93, 94, 95, 96, 97, 98, 99, 101, 102, 104, 105, 106, 107, 237

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-Cyclopropyl-7-(4-fluorobenzyl)-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-morpholin-4-ylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

4-Hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(5-Fluoro-2-pyridinyl)methyl]-4-hydroxy-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-1-(cyclopropylmethyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-(1,3-thiazol-2-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-[(2-hydroxyethyl)oxy]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamid;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-hydroxy-1-methylethyl]-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(2-hydroxypropyl]-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
and pharmaceutically acceptable salts thereof.

16. (currently amended) A compound selected from the group consisting of example numbers 73, 114, 116, 122, 125, 145, 146, 148, 149, 153, 154, 155, 156, 162, 168, 169, 170, 173, 180, 185, 186, 188, 189, 190, 203, 206, 208, 209, 210, 227, 231, 234, 237, 245, 253, 260, 261, 262, 279, 292, 296, 297, 301, 302, 310, 327, 339, 340, 343, 359, 360, 363, 366, 367, 377, 380, 381, 382, 383, 394, 408, 409, 410, 411, 428, 429, 431, 434, 463, 465, 471, 472, 473, 476, 477, 484, 495, 515, 516, 519, 521, 522, 524, 525, 528, 535, 548, 549, 554, 557, 564, 566, 568, 569, 574, 576, 577, 579, 580, 581, 582, 583, 584, 588, 589, 591, 593, 595, 596, 598, 599, 601, 602, 603, 604, 624, 626, 627, 628, 629, 631, 633, 634, 636, 637, 638, 642, 646, 657, 660, 662, 663, 665, 669, 671, 673, 674, 677, 680, 681, 684, 688, 690, 691, 693, 694, 696, 697, 698

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxybutyl)-2-oxo-1-[3-(2-oxohexahydro-1*H*-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-[3-(methyloxy)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1-methyl-2-(methyloxy)ethyl]-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxypropyl)-2-oxo-1-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-Amino-2-oxoethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-hydroxypropyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(2-methylpropyl)-2-oxo-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-(Cyclopropylmethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxy-1-methylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(3-morpholin-4-ylpropyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(Ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[1-methyl-2-(methyloxy)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(1-pyrrolidinylsulfonyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[1-methyl-2-(methyloxy)ethyl]-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxypropyl)-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(Ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-(4-pyridinylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(1,1-Dioxidotetrahydro-2H-1,2-thiazin-2-yl)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-N-[2-(ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(diethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-[(2-hydroxyethyl)oxy]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-(2,3-dihydroxypropyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(acetylamino)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-[methyl(methylsulfonyl)amino]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-(2-pyridinylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-[(1-methylethyl)oxy]ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(2,4-Difluorophenyl)methyl]-1-[2-(dimethylamino)-2-oxoethyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2S]-2-hydroxypropyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
(±)-1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-{2-[(dimethylamino)sulfonyl]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-[(1*S*)-2-hydroxy-1-methylethyl]-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-[(1*R*)-2-hydroxy-1-methylethyl]-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(Acetylamino)ethyl]-1-ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-[(1*R*)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-{2-[methyl(methylsulfonyl)amino]ethyl}-1-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-*N*-{2-[methyl(methylsulfonyl)amino]ethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[1-(hydroxymethyl)cyclopentyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxy-1-methylethyl)-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-*N*-{2-[(1-methylethyl)sulfonyl]ethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-*N*-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxypropyl)-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(1*H*-imidazol-4-ylmethyl)-*N*-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2*S*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2*R*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-(3-methoxypropyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-*N*-(3-hydroxypropyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[Acetyl(methyl)amino]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(methylamino)-2-oxoethyl]-*N*-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Cyclopropylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Cyclopropylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Cyclopropylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[(Dimethylamino)carbonyl](methyl)amino]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[3-(2,5-dioxo-1-pyrrolidinyl)propyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
N-[2-(acetylamino)ethyl]-1-butyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(acetylamino)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(acetylamino)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-[(2R)-2,3-Dihydroxypropyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-{[(dimethylamino)carbonyl]amino}ethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-{[(dimethylamino)carbonyl]amino}ethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-{[(dimethylamino)carbonyl]amino}ethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1-(hydroxymethyl)-2-methylpropyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-{[(dimethylamino)carbonyl]amino}ethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1-methyl-2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-(2-{[(dimethylamino)carbonyl]amino}ethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(3,4-Difluorophenyl)methyl]-1-[2-(dimethylamino)-2-oxoethyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(3,4-difluorophenyl)methyl]-1-[2-(dimethylamino)-2-oxoethyl]-4-hydroxy-N-[2-hydroxypropyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
methyl {2-[7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-3-({[3-(2-oxo-1-pyrrolidinyl)propyl]amino}carbonyl)-1,5-naphthyridin-1(2H)-yl]ethyl} carbamate;
N-[(2S)-2,3-Dihydroxypropyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-{1-[(methyloxy)methyl]propyl}-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1-(hydroxymethyl)-2-methylpropyl]-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1-(hydroxymethyl)butyl]-2-oxo-1-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[acetyl(methyl)amino]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-Ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(2S)-2-hydroxypropyl]-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-Ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxypropyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[1-methyl-2-(methyloxy)ethyl]-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(4-hydroxybutyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-(2-oxo-2-thiomorpholin-4-ylethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-[Ethyl(methyl)amino]-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-[methyl(methyloxy)amino]-2-oxoethyl]-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(2R)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxypropyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxybutyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(2S)-2-hydroxypropyl]-1-[3-(methyloxy)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-methylethyl]-1-[3-(methyloxy)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-1-[3-(methyloxy)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-[Acetyl(methyl)amino]ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(2R)-2-hydroxypropyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-[Acetyl(methyl)amino]ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxybutyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-[Acetyl(methyl)amino]ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxy-2-methylpropyl)-2-oxo-1-[2-(2-oxo-1-piperidinyl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-methyl-1-[2-(methylamino)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-1-[2-(isopropylamino)-2-oxoethyl]-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-methyl-1-{2-[(methyloxy)amino]-2-oxoethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-1-{2-[(2-methoxyethyl)amino]-2-oxoethyl}-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[Acetyl(methyl)amino]ethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-Cyclopropyl-N-[(2R)-2,3-dihydroxypropyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Ethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(tert-Butylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(2-oxo-1-piperidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1-[3-(2-oxo-1-piperidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1-[3-(2-oxo-1-piperidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2-oxo-1-[3-(2-oxo-1-piperidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-{2-[(Cyclopropylmethyl)amino]-2-oxoethyl}-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-(2-{[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-[4-(methyloxy)phenyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Ethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2S)-2-hydroxypropyl]-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxypropyl)-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2R)-2-hydroxypropyl]-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(3-hydroxybutyl)-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1S)-2-hydroxy-1-methylethyl]-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-methyl-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[1R)-2-hydroxy-1-methylethyl]-2-oxo-1-[3-(2-oxohexahydro-1H-azepin-1-yl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
and pharmaceutically acceptable salts thereof.

17. (currently amended) A compound selected from the group consisting of ~~example numbers 12, 36, 37, 49, 84, 89, 91, 93, 95, 96, 101, 237~~

7-Benzyl-4-hydroxy-N-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(5-Fluoro-2-pyridinyl)methyl]-4-hydroxy-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-(4-Fluorobenzyl)-4-hydroxy-N-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-N-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
and pharmaceutically acceptable salts thereof.

18. (original) A compound selected from 7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide; 1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide; and pharmaceutically acceptable salts thereof.

19. (currently amended) A compound according to ~~any of claims 1-18~~ claim 1 wherein the pharmaceutically acceptable salt is a sodium salt.

20. (currently amended) A method of treatment of a viral infection in a human comprising administering to said human an antiviral effective amount of a compound according to ~~any of~~ claims 1 to 18 claim 1.

21. (original) A method according to claim 20 wherein the viral infection is a HIV infection.

22. canceled

23. canceled

24. canceled

25. (currently amended) A pharmaceutical composition comprising an effective amount of a compound according to ~~any of~~ claims 1 to 18 claim 1 together with a pharmaceutically acceptable carrier.

26. (original) A pharmaceutical composition according to claim 25 in the form of a tablet or capsule.

27. (original) A pharmaceutical composition according to claim 25 in the form of a liquid or suspension.

28. (currently amended) A method of treatment of a viral infection in a human comprising administering to said human a composition comprising a compound according to ~~any of~~ claims 1 to 18 claim 1 and another therapeutic agent.

29. (original) The method according to claim 28 wherein the viral infection is an HIV infection.

30. (original) A composition according to claim 25, wherein said composition comprises at least one additional therapeutic agent selected from the group consisting of (1-alpha, 2-beta,

3-alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxetanocin-G), TMC-114, BMS-232632, acyclic nucleosides [e.g. acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir], acyclic nucleoside phosphonates [e.g. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene)-2,2-dimethylpropanoic acid (bis-POM PMEA, adefovir dipivoxil), [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid (tenofovir), (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid bis-(isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA)], ribonucleotide reductase inhibitors (e.g. 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone and hydroxyurea), nucleoside reverse transcriptase inhibitors (e.g. , 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine (ddI, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)-beta-D-2,6-diaminopurine dioxolane (DAPD), 3'-Azido-2',3'-dideoxythymidine-5'-H-phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'-fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir), , 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G) and ribavirin), protease inhibitors (e.g. indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5-yl oxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide (KNI-272), 4R-(4alpha,5alpha,6beta)]-1,3-bis[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5-trifluoromethylpyridinyl)-sulfonylamino]phenyl]propyl]-4-hydroxy-6alpha-phenethyl-6beta-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N-(methoxycarbonyl)-l-tert-leucylamino]-4-phenylbutyl-N^{alpha}-(methoxycarbonyl)-N'-[4-(2-pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)-


Hydroxy-1(S)-indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(1-(4-benzo[b]furanyl)methyl)-2(S)-N'-(tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A), and GW 433908), interferons such as α -interferon, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyridamole; pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin, phosphonoformic acid, as well as immunomodulators such as interleukin II or thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD4 and genetically engineered derivatives thereof, non-nucleoside reverse transcriptase inhibitors (NNRTIs) for example, TMC-120, TMC-125, nevirapine (BI-RG-587), alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dichlorobenzeneacetamide (loviride), 1-[3-(isopropylamino)-2-pyridyl]-4-[5-(methanesulfonamido)-1H-indol-2-ylcarbonyl]piperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12-Hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11,12-dihydro-2H, 6H, 10H-benzo(1, 2-b:3, 4-b':5, 6-b")tropyran-2-one ((+) calanolide A), (4S)-6-Chloro-4-[1E]-cyclopropylethenyl)-3,4-dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone (DPC-083), 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-442), 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1H-imidazol-2-ylmethyl carbamate (capravirine), glycoprotein 120 antagonists [e.g. PRO-2000, PRO-542 and 1,4-bis[3-[(2, 4-dichlorophenyl)carbonylamino]-2-oxo-5,8-disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1, 4-dihydrazone (FP-21399)], cytokine antagonists [e.g. reticulose (Product-R), 1,1'-azobis-formamide (ADA), and 1,11-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD-3100)], and fusion inhibitors for example T-20 and T-124.

31. (original) A method according to claim 28, wherein said therapeutic agent is selected from the group consisting of (1-alpha, 2-beta, 3-alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxymethyl)-2-oxetanosyl]adenine (oxtanocin-G), acyclic nucleosides [e.g. acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir], acyclic nucleoside phosphonates [e.g. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPc), [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene)-2,2-dimethylpropanoic acid (bis-POM PMEA, adefovir dipivoxil), [(1R)-2-(6-amino-9H-purin-

9-yl)-1-methylethoxy]methyl]phosphonic acid (tenofovir), (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid bis-(isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA)], ribonucleotide reductase inhibitors (e.g. 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone and hydroxyurea), nucleoside reverse transcriptase inhibitors (e.g. , 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine (ddI, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)-beta-D-2,6-diaminopurine dioxolane (DAPD), 3'-Azido-2',3'-dideoxythymidine-5'-H-phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), as (-)-*cis*-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), or *cis*-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'-fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-*cis*-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir), , 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G) and ribavirin), protease inhibitors (e.g. indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5-yloxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5- dimethyl-1,3-thiazolidine-4-carboxamide (KNI-272), 4R-*(4alpha,5alpha,6beta)*]-1,3-bis[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5-trifluoromethylpyridinyl)-sulfonylamino]phenyl]propyl]-4- hydroxy-6*alpha*-phenethyl-6*beta*-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N-(methoxycarbonyl)-l-tert-leucylamino]-4-phenylbutyl-N ^{alpha}-(methoxycarbonyl)-N'-[4-(2-pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)-Hydroxy-1(S)-indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(4-benzo[b]furanyl)methyl)-2(S)-N'-(tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A), and GW 433908), interferons such as α -interferon, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyridamole; pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin, phosphonoformic acid, as well as immunomodulators such as interleukin II or thymosin, granulocyte macrophage colony stimulating factors, erythropoietin, soluble CD4 and genetically engineered derivatives

thereof, non-nucleoside reverse transcriptase inhibitors (NNRTIs) [e.g. nevirapine (BI-RG-587), alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-benzeneacetamide (loviride), 1-[3-(isopropylamino)-2-pyridyl]-4-[5-(methanesulfonamido)-1H-indol-2-ylcarbonyl]piperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12-Hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11,12-dihydro-2H, 6H, 10H-benzo(1, 2-b:3, 4-b')5, 6-b")tropyran-2-one ((+) calanolide A), (4S)-6-Chloro-4-[1E]-cyclopropylethenyl)-3,4- dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone (DPC-083), 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-442), 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1H-imidazol-2-ylmethyl carbamate (capravirine)], glycoprotein 120 antagonists [e.g. PRO-2000, PRO-542 and 1,4-bis[3-[(2, 4-dichlorophenyl)carbonylamino]-2-oxo-5,8-disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1, 4-dihydrazone (FP-21399)], cytokine antagonists [e.g. reticulose (Product-R), 1,1'-azobis-formamide (ADA), and 1,11-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD-3100)], and fusion inhibitors (e.g. T-20 and T-1249).

32. (currently amended) A process for the preparation of a compound of formula 4h




4h

wherein R¹ is one or more substituents independently selected from hydrogen, hydroxy, CN, N(R^aR^b), C₁₋₈alkyl, C₃₋₇ cycloalkyl, halogen and C₁₋₈ alkoxy, wherein R^a and R^b are independently hydrogen, NO₂, OR^c, C(O)R^c, C₁₋₈alkyl optionally substituted with OR^c, C₆₋₁₄aryl, S(O)_{2m}R^e S(O)_mR^c or heterocycle, wherein R^c is hydrogen, C₁₋₈alkyl, or C₆₋₁₄aryl and wherein m is 1 or 2;


comprising:

(a) treating a compound of formula 4a




with alkyllithium reagents or magnesium;


(b) reacting a compound of formula 4a with a compound of formula 4b




to form a compound of formula 4c




(c) reducing a compound of formula 4c to form a compound of formula 4d




(d) nitrating a compound of formula 4d in an acid solvent to form a compound of formula 4e



(e) treating a compound of formula 4e with phosphorous oxybromide in an inert solvent to form a compound of formula 4f



(f) carbonylating a compound of formula 4f in the presence of palladium to form a compound of formula 4g



(g) reducing a compound of formula 4g to form a compound of formula 4h.

33. (new) 7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

34. (new) 7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide sodium salt.

35. (new) A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

36. (new) A pharmaceutical composition comprising an effective amount of 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

37. (new) A pharmaceutical composition according to claim 36 in the form of a tablet or capsule.

38. (new) A pharmaceutical composition according to claim 36 in the form of a liquid or suspension.

39. (new) A method of treatment of an HIV infection in a human comprising administering to said human a composition comprising 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

40. (new) A pharmaceutical composition according to claim 36 wherein said composition comprises at least one additional therapeutic agent.